
MAZE Stock Forecast & Price Target
MAZE Analyst Ratings
Bulls say
Maze Therapeutics Inc. is leveraging its innovative Compass platform to identify and target genetic variants for the development of novel precision medicines, specifically addressing chronic kidney disease with its promising programs, MZE829 and MZE782. Preliminary Phase 1 data indicate significant efficacy signals, with MZE782 demonstrating a 39-fold increase in urinary phenylalanine and supportive pharmacokinetic profiles, suggesting a competitive advantage over existing treatments in the market. Furthermore, the anticipated regulatory momentum for MZE829, bolstered by improved diagnosis and treatment protocols, enhances the likelihood of accelerated approval, positioning Maze Therapeutics favorably within the biopharmaceutical landscape.
Bears say
The analysis of Maze Therapeutics, Inc. indicates a cautious outlook primarily due to the risks associated with its investigational drug inaxaplin, which may lead to an inflated perception of its efficacy. Additionally, the complexities surrounding chronic kidney disease (CKD), particularly in patients experiencing variable responses to SGLT2 inhibitors and the potential for significant eGFR declines, contribute to substantial uncertainties in trial outcomes. Furthermore, indications that a significant portion of patients may not respond adequately to existing therapies amplify concerns regarding the commercial viability and success of the company’s precision medicine initiatives.
This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MAZE Analyst Forecast & Price Prediction
Start investing in MAZE
Order type
Buy in
Order amount
Est. shares
0 shares